Section Edited by Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosisAna Belen Moreno-Castaño, Sara Fernández, Helena Ventosa, Marta Palomo, Julia Martinez-Sanchez, Alex Ramos, Valentín Ortiz-Maldonado, Julio Delgado, Carlos Fernández de Larrea, Alvaro Urbano-Ispizua, Olaf Penack, J M Nicolás, Adrian Téllez, Gines Escolar, Enric CarrerasSee the full list of authors
12 April 2023
Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinomaBradley Sinclair White, Sivasish Sindiri, Victoria Hill, Billel Gasmi, Shirley Nah, Jared J Gartner, Todd D Prickett, Yong Li, Devikala Gurusamy, Paul Robbins, Steven A Rosenberg, Vid Leko
12 April 2023
Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into the CD247 locusSangjoon Lah, Segi Kim, In Kang, Hyojin Kim, Cedric Hupperetz, Hyuncheol Jung, Hyeong Ryeol Choi, Young-Ho Lee, Hyeon-Ki Jang, Sangsu Bae, Chan Hyuk Kim
5 April 2023
Serpin B9 controls tumor cell killing by CAR T cellsThomas Kimman, Anne Slomp, Anne Martens, Sarah Grabherr, Shuang Li, Eline van Diest, Jan Meeldijk, Jurgen Kuball, Monique C Minnema, Eric Eldering, Niels Bovenschen, Zsolt Sebestyén, Victor Peperzak
17 March 2023
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineeringKathryn R Michels, Alyssa Sheih, Susana A Hernandez, Alissa H Brandes, Don Parrilla, Blythe Irwin, Anai M Perez, Hung-An Ting, Christopher J Nicolai, Timothy Gervascio, Seungjin Shin, Mark D Pankau, Mason Muhonen, Jessica Freeman, Sarah GouldSee the full list of authors
14 March 2023
All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myelomaZiyi Peng, Jingya Wang, Jing Guo, Xin Li, Sheng Wang, Ying Xie, Hongmei Jiang, Yixuan Wang, Mengqi Wang, Meilin Hu, Qian Li, Yafei Wang, Jian-Qing Mi, Zhiqiang Liu
14 March 2023
CD47 expression is critical for CAR T-cell survival in vivoAlex N Beckett, Peter Chockley, Shondra M Pruett-Miller, Phuong Nguyen, Peter Vogel, Heather Sheppard, Giedre Krenciute, Stephen Gottschalk, Christopher DeRenzo
14 March 2023
Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumorsKonstantinos Lontos, Yiyang Wang, Supriya K Joshi, Andrew T Frisch, McLane J Watson, Alok Kumar, Ashley V Menk, Yupeng Wang, Rachel Cumberland, Jason Lohmueller, Esteban Carrizosa, Benjamin Boyerinas, Greg M Delgoffe
13 March 2023
Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in miceXinyue Dong, Jun Ren, Zohreh Amoozgar, Somin Lee, Meenal Datta, Sylvie Roberge, Mark Duquette, Dai Fukumura, Rakesh K Jain
10 March 2023
Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor abilityJianghui Tang, Jianpeng Sheng, Qi Zhang, Yongtao Ji, Xun Wang, Junlei Zhang, Jiangchao Wu, Jinyuan Song, Xueli Bai, Tingbo Liang
27 February 2023
